Longitudinal non‐adherence predicts treatment escalation in paediatric ulcerative colitis
- 2 August 2019
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 50 (8) , 911-918
Abstract
Summary: Background: Medication non‐adherence in paediatric ulcerative colitis (UC) has been associated with negative health outcomes including flares in disease activity. However, no studies to date have examined longitudinal adherence to maintenance medication in a prospective controlled trial.Aims: To determine whether objectively measured adherence to standardised mesalazine (mesalamine) therapy over time was related to remission at 52 weeks and the need for treatment escalation in newly diagnosed paediatric patients with UCMethods: PROTECT (NCT01536535) was a prospective, inception cohort, multi‐site study of paediatric patients aged 4‐17 years with newly diagnosed UC followed for 52 weeks. Patients received standardised mesalazine, with pre‐established criteria for escalation to thiopurines or anti‐TNFα inhibitors. Patients used pill bottles with electronic caps to monitor mesalazine adherence. We tested whether longitudinal adherence to mesalazine predicted steroid‐free remission at week 52 (i.e. quiescent disease on mesalazine alone with no corticosteroids ≥4 weeks prior) and need for treatment escalation (i.e. introduction of immunomodulators, calcineurin‐inhibitors or anti‐TNFα inhibitors).Results: Among 268 patients, average mesalazine adherence trajectories did not predict week 52 steroid‐free remission. Declining adherence over time strongly predicted treatment escalation (β = −.037, P = .001). By month 6, adherence rate ≤85.7% was associated with treatment escalation.Conclusions: Non‐adherence may have affected therapeutic efficacy of standardised mesalazine, thereby contributing to need for treatment escalation. Routine adherence monitoring for at least 6 months following treatment initiation and addressing adherence difficulties early in the disease course are recommended.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (5U01DK095745, AT009708, DK043351, P30 DK078392)
This publication has 33 references indexed in Scilit:
- Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US PopulationDigestive Diseases and Sciences, 2012
- Long‐term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10‐year retrospective cohort from the veterans affairs healthcare systemAlimentary Pharmacology & Therapeutics, 2012
- Treatment Adherence in Adolescents With Inflammatory Bowel Disease: The Collective Impact of Barriers to Adherence and Anxiety/Depressive SymptomsJournal of Pediatric Psychology, 2011
- Association of Disease, Adolescent, and Family Factors with Medication Adherence in Pediatric Inflammatory Bowel DiseaseJournal of Pediatric Psychology, 2010
- Barriers to Oral Medication Adherence for Adolescents with Inflammatory Bowel DiseaseJournal of Pediatric Psychology, 2009
- Making therapeutic decisions in inflammatory bowel disease: the role of patientsCurrent Opinion in Gastroenterology, 2009
- Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel diseaseInflammatory Bowel Diseases, 2009
- Systematic review: impact of non‐adherence to 5‐aminosalicylic acid products on the frequency and cost of ulcerative colitis flaresAlimentary Pharmacology & Therapeutics, 2008
- Medication Non-adherence is Associated with Increased Medical Health Care CostsDigestive Diseases and Sciences, 2007
- Nonadherence With Thiopurine Immunomodulator and Mesalamine Medications in Children with Crohn DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2007